RCC Immune Microenvironment Subsequent to Targeted Therapy: A Friend or a Foe?

被引：10

作者：

Chen, Wenjin ^{[1
]}

Pan, Xiuwu ^{[1
]}

Cui, Xingang ^{[1
]}

机构：

[1] Second Mil Med Univ, Dept Urol, Affiliated Hosp 3, Shanghai, Peoples R China

来源：

FRONTIERS IN ONCOLOGY | 2020年 / 10卷

基金：

中国国家自然科学基金;

关键词：

renal cell carcinoma; tumor microenvironment; immune cells; targeted therapy; immunotherapy; RENAL-CELL CARCINOMA; TUMOR-ASSOCIATED MACROPHAGES; REGULATORY T-CELLS; CANCER-ASSOCIATED FIBROBLASTS; ANTIANGIOGENIC THERAPY; SUPPRESSOR-CELLS; DENDRITIC CELLS; KIDNEY CANCER; SUNITINIB; EXPRESSION;

D O I：

10.3389/fonc.2020.573690

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Renal cell carcinoma (RCC) is composed of different subtypes with distinct molecular and histological tumor heterogeneity. Although the advent of various targeted therapies has improved the survival of patients with advanced RCC over the past 15 years (since 2006), few cases experienced complete response due to drug resistance. Recent studies have demonstrated that the outcomes following targeted therapies are potentially associated with intricate cross-links between immune responses and suppressors in the tumor microenvironment (TME). In addition, progress on drug research and development enhances our awareness and understanding about immunotherapy and combined treatment. In this review article, we intend to make a comprehensive summary about TME and its alterations following targeted therapies, provide valid evidence in this aspect, and discuss optimal matches between targeted therapy and immunotherapy.

引用

页数：10

共 97 条

[61] Myeloid-Derived Suppressor Cell Subset Accumulation in Renal Cell Carcinoma Parenchyma Is Associated with Intratumoral Expression of IL1β, IL8, CXCL5, and Mip-1α [J].

Najjar, Yana G. ;

Rayman, Patricia ;

Jia, Xuefei ;

Pavicic, Paul G., Jr. ;

Rini, Brian I. ;

Tannenbaum, Charles ;

Ko, Jennifer ;

Haywood, Samuel ;

Cohen, Peter ;

Hamilton, Thomas ;

Diaz-Montero, C. Marcela ;

Finke, James .

CLINICAL CANCER RESEARCH, 2017, 23 (09) :2346-2355

[62]

Nirschl TR, 2020, AM J CLIN EXP UROL, V8, P48

[63] The effect of anti-VEGF therapy on immature myeloid cell and dendritic cells in cancer patients [J].

Osada, Takuya ;

Chong, Gabriel ;

Tansik, Robert ;

Hong, Timothy ;

Spector, Neil ;

Kumar, Rakesh ;

Hurwitz, Herbert I. ;

Dev, Inderjit ;

Nixon, Andrew B. ;

Lyerly, H. Kim ;

Clay, Timothy ;

Morse, Michael A. .

CANCER IMMUNOLOGY IMMUNOTHERAPY, 2008, 57 (08) :1115-1124

[64] Patient-reported outcomes in a phase 2 study comparing atezolizumab alone or with bevacizumab vs sunitinib in previously untreated metastatic renal cell carcinoma [J].

Pal, Sumanta K. ;

McDermott, David F. ;

Atkins, Michael B. ;

Escudier, Bernard ;

Rini, Brian I. ;

Motzer, Robert J. ;

Fong, Lawrence ;

Joseph, Richard W. ;

Oudard, Stephane ;

Ravaud, Alain ;

Bracarda, Sergio ;

Suarez, Cristina ;

Lam, Elaine T. ;

Choueiri, Toni K. ;

Ding, Beiying ;

Quach, Caroleen ;

Hashimoto, Kenji ;

Schiff, Christina ;

Piault-Louis, Elisabeth ;

Powles, Thomas .

BJU INTERNATIONAL, 2020, 126 (01) :73-82

[65] T Regulatory Cells and Priming the Suppressive Tumor Microenvironment [J].

Paluskievicz, Christina M. ;

Cao, Xuefang ;

Abdi, Reza ;

Zheng, Pan ;

Liu, Yang ;

Bromberg, Jonathan S. .

FRONTIERS IN IMMUNOLOGY, 2019, 10

[66] Targeted therapies for renal cell carcinoma [J].

Posadas, Edwin M. ;

Limvorasak, Suwicha ;

Figlin, Robert A. .

NATURE REVIEWS NEPHROLOGY, 2017, 13 (08) :496-511

[67] The Intersection between Tumor Angiogenesis and Immune Suppression [J].

Rahma, Osama E. ;

Hodi, F. Stephen .

CLINICAL CANCER RESEARCH, 2019, 25 (18) :5449-5457

[68] Immune cells and angiogenesis [J].

Ribatti, Domenico ;

Crivellato, Enrico .

JOURNAL OF CELLULAR AND MOLECULAR MEDICINE, 2009, 13 (9A) :2822-2833

[69] Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial [J].

Rini, Brian I. ;

Powles, Thomas ;

Atkins, Michael B. ;

Escudier, Bernard ;

McDermott, David F. ;

Suarez, Cristina ;

Bracarda, Sergio ;

Stadler, Walter M. ;

Donskov, Frede ;

Lee, Jae Lyun ;

Hawkins, Robert ;

Ravaud, Alain ;

Alekseev, Boris ;

Staehler, Michael ;

Uemura, Motohide ;

De Giorgi, Ugo ;

Mellado, Begona ;

Porta, Camillo ;

Melichar, Bohuslav ;

Gurney, Howard ;

Bedke, Jens ;

Choueiri, Toni K. ;

Parnis, Francis ;

Khaznadar, Tarik ;

Thobhani, Alpa ;

Li, Shi ;

Piault-Louis, Elisabeth ;

Frantz, Gretchen ;

Huseni, Mahrukh ;

Schiff, Christina ;

Green, Marjorie C. ;

Motzer, Robert J. .

LANCET, 2019, 393 (10189) :2404-2415

[70] Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma [J].

Rini, Brian I. ;

Plimack, Elizabeth R. ;

Stus, Viktor ;

Gafanov, Rustem ;

Hawkins, Robert ;

Nosov, Dmitry ;

Pouliot, Frederic ;

Alekseev, Boris ;

Soulieres, Denis ;

Melichar, Bohuslav ;

Vynnychenko, Ihor ;

Kryzhanivska, Anna ;

Bondarenko, Igor ;

Azevedo, Sergio J. ;

Borchiellini, Delphine ;

Szczylik, Cezary ;

Markus, Maurice ;

McDermott, Raymond S. ;

Bedke, Jens ;

Tartas, Sophie ;

Chang, Yen-Hwa ;

Tamada, Satoshi ;

Shou, Qiong ;

Perini, Rodolfo F. ;

Chen, Mei ;

Atkins, Michael B. ;

Powles, Thomas .

NEW ENGLAND JOURNAL OF MEDICINE, 2019, 380 (12) :1116-1127

← 1 2 3 4 5 6 7 8 9 10 →